377740.Ks

The company's capital structure is characterized by a very low debt-to-equity ratio of 0.0, indicating a strong equity position relative to liabilities. However, the company's liquidity position is assessed as medium, with a current ratio of 31.01, suggesting a high level of short-term assets relative to liabilities, but with a negative free cash flow of -106,812,726,600 KRW, which indicates significant cash outflows from operations after capital expenditures.

Profitability metrics show a return on equity of -0.0579 and a return on assets of -0.0562, both of which are negative, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. These figures are below the typical expectations for the pharmaceutical industry, which generally requires high R&D investment and long development cycles before achieving profitability.

The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no additional geographic or segment breakdown provided in the available data. This lack of diversification may expose the company to higher risk if its primary product or market experiences a downturn.

The company's growth trajectory is uncertain, with a net loss of 87,497,889,500 KRW reported in the latest financial period. The operating cash flow of 14,381,482,560 KRW is positive, but the negative free cash flow suggests that the company is investing heavily in capital expenditures, which may be a sign of long-term growth initiatives or a response to market pressures.

Risk factors include the company's negative net cash position after subtracting total debt, which could limit its ability to fund operations or invest in growth opportunities without external financing. The dilution potential is assessed as low, with no significant changes in shares outstanding between basic and diluted shares.

Recent events include the company's continued investment in capital expenditures, as evidenced by the -8,269,915,900 KRW outflow in the latest period. No specific recent filings or transcripts are provided in the available data to indicate strategic shifts or new product launches.